CNBC: Big Pharma’s billion-dollar scramble to invest in start-ups to fuel innovation
“…Despite growing recognition of [the threat of antimicrobial resistance], there is an early stage funding gap for new treatments. … In response, industry giants like Novo Holdings — which has big stakes in Danish drugmaker Novo Nordisk — Merck, Johnson & Johnson, Sanofi, and others are looking to become more entrepreneurial. Increasingly, these big players are setting up venture capital funds and investing in start-ups and licensing technology to fuel their own drug pipelines. Many are also outsourcing R&D, while reducing product development efforts internally…” (Ioannou, 3/28).